Drugs / GSK3845097
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05943990 | Dec 2020 → Oct 2022 | neoplasm | Adaptimmune | Terminated | No outcome recorded |
| Phase 1 | NCT04526509 | Dec 2020 → Jun 2023 | neoplasm | Adaptimmune | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3845097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04526509 ↗ |
| Modality | Cell therapy | “Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NY ESO 1 and LAGE 1a” NCT05943990 ↗ |
| Route | Intravenous | “GSK3845097, as IV infusion” NCT04526509 ↗ |